Vericel Corp - Strategy, SWOT and Corporate Finance Report

Vericel Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. The company is also developing ixmyelocel-T technology, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). It has manufacturing facilities in Cambridge, Massachusetts; Ann Harbour, Michigan and Kastrup, Denmark. The company sells its products through cell therapy specialists. Vericel is headquartered in Cambridge, Massachusetts, the US.

Scope

  • Detailed information on Vericel Corp required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Vericel Corp in the form of a SWOT analysis
  • An in-depth view of the business model of Vericel Corp including a breakdown and examination of key business segments
  • News about Vericel Corp, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Vericel Corp and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Vericel Corp as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Vericel Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

TiGenix Inc

Miltenyi Biotec Inc

Geistlich Pharma North America Inc

Cytori Therapeutics Inc

Compass Biomedical Inc

Avita Medical Americas LLC

AdiSave Inc

TiGenix Inc

Miltenyi Biotec Inc

Geistlich Pharma North America Inc

Cytori Therapeutics Inc

Compass Biomedical Inc

Avita Medical Americas LLC

AdiSave Inc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Vericel Corp - Key Facts

Vericel Corp ...

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Vericel Corp - Key Facts

Vericel Corp - Key Employees

Vericel Corp - Key Employee Biographies

Vericel Corp - Major Products and Services

Vericel Corp - History

Vericel Corp - Company Statement

Vericel Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Vericel Corp - Business Description

Product Category: Carticel and MACI

Performance

Product Category: Epicel

Overview

Performance

Product Category: License Revenue

Overview

Performance

Product Category: MACI

Overview

R&D Overview

Vericel Corp - Corporate Strategy

Vericel Corp - SWOT Analysis

SWOT Analysis - Overview

Vericel Corp - Strengths

Vericel Corp - Weaknesses

Vericel Corp - Opportunities

Vericel Corp - Threats

Vericel Corp - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Vericel Corp, Medical Equipment, Deals By Year, 2013 to YTD 2019

Vericel Corp, Medical Equipment, Deals By Type, 2013 to YTD 2019

Vericel Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 07, 2019: Vericel reports first quarter 2019 financial results and raises full year 2019 revenue guidance

Feb 26, 2019: Vericel announces fourth quarter and full-year 2018 financial results

Aug 20, 2018: Vericel names Jonathan Hopper as chief medical officer

Aug 06, 2018: Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance

May 08, 2018: Vericel Reports First Quarter 2018 Financial Results

Mar 05, 2018: Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Vericel Corp, Key Facts

Vericel Corp, Key Employees

Vericel Corp, Key Employee Biographies

Vericel Corp, Major Products and Services

Vericel Corp, History ...

List of Tables

Vericel Corp, Key Facts

Vericel Corp, Key Employees

Vericel Corp, Key Employee Biographies

Vericel Corp, Major Products and Services

Vericel Corp, History

Vericel Corp, Other Locations

Vericel Corp, Subsidiaries

Vericel Corp, Key Competitors

Vericel Corp, Ratios based on current share price

Vericel Corp, Annual Ratios

Vericel Corp, Annual Ratios (Cont...1)

Vericel Corp, Interim Ratios

Vericel Corp, Medical Equipment, Deals By Year, 2013 to YTD 2019

Vericel Corp, Medical Equipment, Deals By Type, 2013 to YTD 2019

Vericel Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Vericel Corp, Performance Chart (2014 - 2018)

Vericel Corp, Ratio Charts

Vericel Corp, Medical Equipment, Deals By Year, 2013 to YTD 2019 ...

List of Figures

Vericel Corp, Performance Chart (2014 - 2018)

Vericel Corp, Ratio Charts

Vericel Corp, Medical Equipment, Deals By Year, 2013 to YTD 2019

Vericel Corp, Medical Equipment, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports